New surprises of suppressor of cytokine signalling in liver fibrosis

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 4, 2014, Pages 415-426

  Cheng, Chang ^a   Huang, Cheng ^a   Ma, Tao Tao ^a   Xu, Tao ^a   Wang, Ya Rui ^a   Zhang, Lei ^a   Jun, Li ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Epigenetics; Liver fibrosis; Macrophages; Suppressor of cytokine signalling; Target

Indexed keywords

DNA; HISTONE H3; HISTONE H4; MICRORNA; MICRORNA 122; MICRORNA 155; MICRORNA 9; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN SH2; RNA POLYMERASE II; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; CYTOKINE;

CELL ACTIVATION; CHROMATIN STRUCTURE; CHROMOSOME 10; DNA METHYLATION; EPIGENETICS; FIBROGENESIS; HISTONE MODIFICATION; HUMAN; LIVER FIBROSIS; MACROPHAGE; MODULATION; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN FUNCTION; PROTEIN RNA BINDING; REVIEW; SIGNAL TRANSDUCTION; STELLATE CELL; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; ANIMAL; GENETICS; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

ANIMALS; CYTOKINES; EPIGENOMICS; HUMANS; LIVER CIRRHOSIS; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84896366366     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.885953     Document Type: Review

References (82)

1. Ahmad R, Ahmad A. Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches. Saudi J Gastroenterol 2012;18:155
2. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011;25:195-206
3. Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010;7:425-36
4. Wang Y, Li J, Wang X, et al. Hepatic stellate cells, liver innate immunity, and hepatitis C virus. J Gastroenterol Hepatol 2013;28(Suppl 1):112-15
5. Salguero Palacios R, Roderfeld M, Hemmann S, et al. Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice. Lab Invest 2008;88:1192-203
6. Wynn T, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 2010;30:245-57
7. Liu C, Tao Q, Sun M, et al. Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in hepatic fibrosis in rats. Lab Invest 2010;90:1805-16
8. Palmer DC, Restifo NP. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol 2009;30:592-602
9. Larsen L, Ropke C. Suppressors of cytokine signalling: SOCS. APMIS 2002;110:833-44
10. Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 2001;19:378-87
11. Hernandez-Vargas P, Lopez-Franco O, Sanjuan G, et al. Suppressors of cytokine signaling regulate angiotensin II-activated Janus kinase-signal transducers and activators of transcription pathway in renal cells. J Am Soc Nephrol 2005;16:1673-83
12. Tamiya T, Kashiwagi I, Takahashi R, et al. Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3. Arterioscler Thromb Vasc Biol 2011;31:980-5
13. Strebovsky J, Walker P, Dalpke AH. Suppressor of cytokine signaling proteins as regulators of innate immune signaling. Front Biosci (Landmark Ed) 2012;17:1627-39
14. Baetz A, Frey M, Heeg K, et al. Suppressor of cytokine signaling (SOCS) proteins indirectly regulate toll-like receptor signaling in innate immune cells. J Biol Chem 2004;279:54708-15
15. Auernhammer CJ, Bousquet C, Chesnokova V, et al. SOCS proteins: modulators of neuroimmunoendocrine functions. Impact on corticotroph LIF signaling. Ann NY Acad Sci 2000;917:658-64
16. Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 2004;22:503-29
17. Hu G, Zhou R, Liu J, et al. MicroRNA-98 and let-7 confer cholangiocyte expression of cytokineinducible Src homology 2-containing protein in response to microbial challenge. J Immunol 2009;183:1617-24
18. Inagaki-Ohara K, Kondo T, Ito M, et al. SOCS, inflammation, and cancer. JAKSTAT 2013;2:e24053
19. Das G, Yao R, Ma Y-L, et al. MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1. PLoS One 2012;7:e46082
20. Cardoso AL, Guedes JR, Pereira de Almeida L, et al. miR-155 modulates microglia-mediated immune response by down-regulating SOCS-1 and promoting cytokine and nitric oxide production. Immunology 2012;135:73-88
21. Liu TC, Lin SF, Chang JG, et al. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br J Haematol 2003;123:654-61
22. Sutherland KD, Lindeman GJ, Choong DY, et al. Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 2004;23:7726-33
23. Sobti RC, Singh N, Hussain S, et al. Aberrant promoter methylation and loss of suppressor of cytokine signalling-1 gene expression in the development of uterine cervical carcinogenesis. Cell Oncol (Dordr) 2011;34:533-43
24. Tokita T, Maesawa C, Kimura T, et al. Methylation status of the SOCS3 gene in human malignant melanomas. Int J Oncol 2007;30:689-94
25. Niwa Y, Kanda H, Shikauchi Y, et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2005;24:6406-17
26. Tischoff I, Hengge UR, Vieth M, et al. Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. Gut 2007;56:1047-53
27. He B, You L, Uematsu K, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 2003;100:14133-8
28. Kobayashi D, Nomoto S, Kodera Y, et al. Suppressor of cytokine signaling 4 detected as a novel gastric cancer suppressor gene using double combination array analysis. World J Surg 2012;36:362-72
29. Lin HY, Lai RH, Lin ST, et al. Suppressor of cytokine signaling 6 (SOCS6) promotes mitochondrial fission via regulating DRP1 translocation. Cell Death Differ 2013;20:139-53
30. Storojeva I, Boulay JL, Ballabeni P, et al. Prognostic and predictive relevance of DNAM-1, SOCS6 and CADH-7 genes on chromosome 18q in colorectal cancer. Oncology 2005;68:246-55
31. Huidobro C, Fernandez AF, Fraga MF. The role of genetics in the establishment and maintenance of the epigenome. Cell Mol Life Sci 2013;70:1543-73
32. Asada K, Asada R, Yoshiji H, et al. DNA cytosine methylation profile in various cancer-related genes is altered in cultured rat hepatocyte cell lines as compared with primary hepatocytes. Oncol Rep 2006;15:1241-8
33. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001;28:29-35
34. Rongrui L, Na H, Zongfang L, et al. Epigenetic mechanism involved in the HBV/HCV-related hepatocellular carcinoma tumorigenesis. Curr Pharm Des 2013;20:1-11
35. Yoshida T. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J Exp Med 2004;199:1701-7
36. Baltayiannis G, Baltayiannis N, Tsianos EV. Suppressors of cytokine signaling as tumor repressors. Silencing of SOCS3 facilitates tumor formation and growth in lung and liver. J BUON 2008;13:263-5
37. Ogata H, Chinen T, Yoshida T, et al. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production. Oncogene 2006;25:2520-30
38. Bian E-B, Huang C, Ma T-T, et al. DNMT1-mediated PTEN hypermethylation confers hepatic stellate cell activation and liver fibrogenesis in rats. Toxicol Appl Pharmacol 2012;264:13-22
39. Leung TM, Wang X, Kitamura N, et al. Osteopontin delays resolution of liver fibrosis. Lab Invest 2013;93:1082-9
40. Komatsu Y, Waku T, Iwasaki N, et al. Global analysis of DNA methylation in early-stage liver fibrosis. BMC Med Genomics 2012;5:5
41. Ben-Zvi T, Yayon A, Gertler A, et al. Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling. J Cell Sci 2006;119:380-7
42. Yoshimura A. Regulation of cytokine signaling by the SOCS and Spred family proteins. Keio J Med 2009;58:73-83
43. Boyle K, Egan P, Rakar S, et al. The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo. Blood 2007;110:1466-74
44. van de Geijn GJ, Gits J, Touw IP. Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling. J Leukoc Biol 2004;76:237-44
45. Sonderegger I, Iezzi G, Maier R, et al. GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J Exp Med 2008;205:2281-94
46. Phan VT, Wu X, Cheng JH, et al. Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci 2013;110:6079-84
47. Bechtel W, McGoohan S, Zeisberg EM, et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 2010;16:544-50
48. Tao H, Huang C, Yang J-J, et al. MeCP2 controls the expression of RASAL1 in the hepatic fibrosis in rats. Toxicology 2011;290:327-33
49. Ueki K, Kondo T, Kahn C R. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004;24:5434-46
50. Zheng RD, Liao LH, Ye J, et al. Effects of SOCS 1/3 gene silencing on the expression of C/EBPalpha and PPARgamma during differentiation and maturation of rat preadipocytes. Pediatr Res 2013;73:263-7
51. Zhao Q, Fan YC, Zhao J, et al. DNA methylation patterns of peroxisome proliferator-activated receptor gamma gene associated with liver fibrosis and inflammation in chronic hepatitis B. J Viral Hepat 2013;20:430-7
52. Bian E-B, Huang C, Wang H, et al. The role of methyl-CpG binding protein 2 in liver fibrosis. Toxicology 2013;309:9-14
53. Imhof A. Epigenetic regulators and histone modification. Brief Funct Genomic Proteomic 2006;5:222-7
54. Qin H, Roberts KL, Niyongere SA, et al. Molecular mechanism of lipopolysaccharide-induced SOCS-3 gene expression in macrophages and microglia. J Immunol 2007;179:5966-76
55. Hirose N, Maekawa T, Shinagawa T, et al. ATF-2 regulates lipopolysaccharideinduced transcription in macrophage cells. Biochem Biophys Res Commun 2009;385:72-7
56. Qin H, Wilson CA, Lee SJ, et al. IFN-beta-induced SOCS-1 negatively regulates CD40 gene expression in macrophages and microglia. FASEB J 2006;20:985-7
57. He Y, Huang C, Zhang SP, et al. The potential of microRNAs in liver fibrosis. Cell Signal 2012;24:2268-72
58. O'Connell RM, Kahn D, Gibson WS, et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010;33:607-19
59. Pogribny IP, Starlard-Davenport A, Tryndyak VP, et al. Difference in expression of hepatic microRNAs miR- 29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest 2010;90:1437-46
60. Yao R, Ma YL, Liang W, et al. MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1. PLoS One 2012;7:e46082
61. Jin D-Y, Collins AS, McCoy CE, et al. miR-19a: an effective regulator of SOCS3 and enhancer of JAK-STAT signalling. PLoS One 2013;8:e69090
62. Povero D, Busletta C, Novo E, et al. Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol 2010;25:1075-91
63. Mann DA, Mann J. Epigenetic regulation of hepatic stellate cell activation. J Gastroenterol Hepatol 2008;23(Suppl 1):S108-11
64. Zeisberg M, Yang C, Martino M, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007;282:23337-47
65. Reichl P, Haider C, Grubinger M, et al. TGF-beta in epithelial to mesenchymal transition and metastasis of liver carcinoma. Curr Pharm Des 2012;18:4135-47
66. Zhu L, Chen H, Zhou D, et al. MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility. Med Oncol 2012;29:1037-43
67. Zhuang G, Wu X, Jiang Z, et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J 2012;31:3513-23
68. Yoshikawa T, Takata A, Otsuka M, et al. Silencing of microRNA-122 enhances interferon-alpha signaling in the liver through regulating SOCS3 promoter methylation. Sci Rep 2012;2:1-10
69. Fujimoto M, Naka T. SOCS1, a negative regulator of cytokine signals and TLR responses, in human liver diseases. Gastroenterol Res Pract 2010;2010:1-7
70. Qin H, Holdbrooks AT, Liu Y, et al. SOCS3 deficiency promotes M1 macrophage polarization and inflammation. J Immunol 2012;189:3439-48
71. D'Argenio G, Cariello R, Tuccillo C, et al. Symbiotic formulation in experimentally induced liver fibrosis in rats: intestinal microbiota as a key point to treat liver damage? Liver Int 2013;33:687-97
72. Seki E, Park E, Fujimoto J. Toll-like receptor signaling in liver regeneration, fibrosis and carcinogenesis. Hepatol Res 2011;41:597-610
73. Gauldie J, Bonniaud P, Sime P, et al. TGF-beta, Smad3 and the process of progressive fibrosis. Biochem Soc Trans 2007;35:661-4
74. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 2004;85:47-64
75. Bian E-B, Huang C, Ma T-T, et al. DNMT1-mediated PTEN hypermethylation confers hepatic stellate cell activation and liver fibrogenesis in rats. Toxicol Appl Pharmacol 2012;264:13-22
76. Croker B A, Kiu H, Nicholson SE. SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 2008;19:414-22
77. Matsukawa A. STAT proteins in innate immunity during sepsis: lessons from gene knockout mice. Acta Med Okayama 2007;61:239-45
78. Cooney RN. Suppressors of cytokine signaling (SOCS): inhibitors of the JAK/STAT pathway. Shock 2002;17:83-90
79. Robinson S M, Mann DA. Role of nuclear factor kappaB in liver health and disease. Clin Sci (Lond) 2010;118:691-705
80. Strebovsky J, Walker P, Lang R, et al. Suppressor of cytokine signaling 1 (SOCS1) limits NFkappaB signaling by decreasing p65 stability within the cell nucleus. FASEB J 2011;25:863-74
81. Orfila C, Lepert JC, Alric L, et al. Immunohistochemical distribution of activated nuclear factor kappaB and peroxisome proliferator-activated receptors in carbon tetrachloride-induced chronic liver injury in rats. Histochem Cell Biol 2005;123:585-93
82. Ageberg M, Rydstrom K, Relander T, et al. The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death. Am J Transl Res 2013;5:170-83